Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197663 | 0.93 | MEN1 (0.53) | NPSR1LTB4RLTB4R2ALDH1A1S1PR1 | |
| SCHEMBL3195513 | 0.88 | S1PR5 (0.57) | NPSR1LTB4RLTB4R2ALDH1A1S1PR5 | |
| SCHEMBL3197489 | 0.88 | CYP2C19 (0.51) | NPSR1LTB4RLTB4R2ALDH1A1S1PR1 | |
| SCHEMBL21243277 | 0.87 | CYP1A2 (0.51) | NPSR1PPARDKDM4E | |
| SCHEMBL8072582 | 0.86 | LTB4R (0.64) | NPSR1LTB4RLTB4R2ALDH1A1PPARD | |
| SCHEMBL8081157 | 0.82 | LTB4R (0.67) | NPSR1LTB4RLTB4R2PPARDMEN1 | |
| SCHEMBL3195349 | 0.82 | MTNR1A (0.61) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL3188601 | 0.81 | MEN1 (0.54) | NPSR1LTB4RLTB4R2ALDH1A1S1PR5 | |
| SCHEMBL10697320 | 0.81 | LTB4R (0.69) | NPSR1LTB4RLTB4R2PPARDMEN1 | |
| SCHEMBL19160930 | 0.81 | LTB4R (0.69) | NPSR1LTB4RLTB4R2PPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | NPSR1 2216/4885LTB4R 1517/4885LTB4R2 1747/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | NPSR1 4560/4885LTB4R 2564/4885LTB4R2 2660/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | NPSR1 2485/4885LTB4R 1769/4885LTB4R2 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.